Pfizer Inc (PFE) 31.76 $PFE
'Mad Money' Lightning Round: Sysco Is Appealing
at The Street - 55 mins ago
Cramer prefers Manitowoc over Middleby and sees Pfizer going higher.
Jim Cramer's 'Mad Money' Recap: Don't Panic About Tech
at The Street - Tue Apr 29, 6:06PM CDT
Some similarities to the 2001 tech bubble exist, but Cramer says it's not time to head for the hills.
Most active New York Stock Exchange-traded stocks
AP - Tue Apr 29, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Apr 29, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Celgene Deal Chief Calls Big Pharma Gutless For Lack of Biotech M&A
at The Street - Tue Apr 29, 3:26PM CDT
Some sharp opinions expressed by healthcare deal-makers at the Allicense 2014 conference.
Is AstraZeneca Really Worth $100 Billion?
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 29, 2:49PM CDT
Pfizer has reportedly made two bids to acquire drug giant AstraZeneca in what could become the biggest drug merger of all time. The deal could eclipse $100 billion in value and would likely consist of both cash and Pfizer stock given that...
Actavis Reporting Q1 Earnings Amid Merger Frenzy
at Investor's Business Daily - Tue Apr 29, 2:33PM CDT
Specialty-drug giant Actavis (ACT) is due to report another quarter of growth, before the market open Wednesday, as the IBD 50 stock continues to swell through acquisitions. Analysts polled by Thomson Reuters estimate Actavis made $3.24 a share in...
AstraZeneca Soars as Pfizer Confirms Buyout Talks - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 1:38PM CDT
AstraZeneca's (AZN) shares soared 12.16% after a statement was released by Pfizer (PFE) confirming that it had discussions with the former regarding a possible merger.
Merck's Spike Leads the Dow Jones Today
Dan Dzombak, The Motley Fool - Motley Fool - Tue Apr 29, 12:36PM CDT
Merck is pulling the Dow Jones Industrial Average up today after the pharmaceutical giant reported better-than-expected earnings. As of 1:20 p.m. EDT the Dow was up 93 points to 16,541. The S&P 500 was up nine points to 1,879. Merck is...
Midday Glance: Pharmaceuticals companies
AP - Tue Apr 29, 12:19PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Why an M&A Surge Could Hurt the Dow Jones Industrials
Dan Caplinger, The Motley Fool - Motley Fool - Tue Apr 29, 11:32AM CDT
The Dow Jones Industrials was up 95 points at 12:30 p.m. EDT, approaching its best level of the day. The Dow largely ignored a slight drop in consumer confidence and some signs of weakness in the housing market , as a relatively solid earnings...
Here's What You Don't Know About Merck & Co. Inc., Today's Best Dow Stock
Alex Planes, The Motley Fool - Motley Fool - Tue Apr 29, 11:13AM CDT
The Dow Jones Industrial Average is off to a solid start in April's final week, and its pharmaceutical components have been major contributors. Pfizer paced Monday's index gain as it pursued another megabuyout , and today's pop is led by ...
Could This Be the Next Health Care Acquisition Target?
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 29, 11:05AM CDT
If you follow the health-care sector in any way, shape, or form, the pay week and a half has been nothing short of incredible. Merger and acquisition activity usually comes in spurts, and true megadeals are rare . But in recent days we have been...
Bristol-Myers Beats Earnings in Q1, Misses on Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 10:52AM CDT
Bristol-Myers (BMY) first quarter 2014 adjusted earnings of 46 cents per share beat the Zacks Consensus Estimate by 2 cents.
Early Glance: Pharmaceuticals companies
AP - Tue Apr 29, 9:30AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Stock Market News for April 29, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 9:06AM CDT
Benchmarks finished Monday’s choppy run mostly higher as investor sentiment following new deals in the health care sector, positive pending home sales data and intense selling pressure on internet stocks
The 3 Reasons Pfizer Wants AstraZeneca
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Apr 29, 8:30AM CDT
Pfizer admitted this morning that it has approached AstraZeneca twice seeking an opportunity to buy the company, most recently last weekend. In a conference call with analysts on Monday, Pfizer's management laid out the case for why AstraZeneca...
Report: Health exchanges' drug coverage confusing
By CARLA K. JOHNSON - AP - Tue Apr 29, 6:03AM CDT
CHICAGO (AP) — The hunt for a health plan that would cover a particular drug or a favorite doctor proved particularly frustrating for many consumers navigating the new insurance exchanges under the federal government's health care overhaul, according to a report released Monday.
'Fast Money' Recap: The Problem With Growth Stocks
at The Street - Tue Apr 29, 4:00AM CDT
The trading panel wonders why Facebook is having a good quarter when Google has been selling off.
'Mad Money' Lightning Round: Sysco Is Appealing
at The Street - 55 mins ago
Cramer prefers Manitowoc over Middleby and sees Pfizer going higher.
Jim Cramer's 'Mad Money' Recap: Don't Panic About Tech
at The Street - Tue Apr 29, 6:06PM CDT
Some similarities to the 2001 tech bubble exist, but Cramer says it's not time to head for the hills.
Most active New York Stock Exchange-traded stocks
AP - Tue Apr 29, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Apr 29, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Celgene Deal Chief Calls Big Pharma Gutless For Lack of Biotech M&A
at The Street - Tue Apr 29, 3:26PM CDT
Some sharp opinions expressed by healthcare deal-makers at the Allicense 2014 conference.
Is AstraZeneca Really Worth $100 Billion?
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 29, 2:49PM CDT
Pfizer has reportedly made two bids to acquire drug giant AstraZeneca in what could become the biggest drug merger of all time. The deal could eclipse $100 billion in value and would likely consist of both cash and Pfizer stock given that...
Actavis Reporting Q1 Earnings Amid Merger Frenzy
at Investor's Business Daily - Tue Apr 29, 2:33PM CDT
Specialty-drug giant Actavis (ACT) is due to report another quarter of growth, before the market open Wednesday, as the IBD 50 stock continues to swell through acquisitions. Analysts polled by Thomson Reuters estimate Actavis made $3.24 a share in...
AstraZeneca Soars as Pfizer Confirms Buyout Talks - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 1:38PM CDT
AstraZeneca's (AZN) shares soared 12.16% after a statement was released by Pfizer (PFE) confirming that it had discussions with the former regarding a possible merger.
Merck's Spike Leads the Dow Jones Today
Dan Dzombak, The Motley Fool - Motley Fool - Tue Apr 29, 12:36PM CDT
Merck is pulling the Dow Jones Industrial Average up today after the pharmaceutical giant reported better-than-expected earnings. As of 1:20 p.m. EDT the Dow was up 93 points to 16,541. The S&P 500 was up nine points to 1,879. Merck is...
Midday Glance: Pharmaceuticals companies
AP - Tue Apr 29, 12:19PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Why an M&A Surge Could Hurt the Dow Jones Industrials
Dan Caplinger, The Motley Fool - Motley Fool - Tue Apr 29, 11:32AM CDT
The Dow Jones Industrials was up 95 points at 12:30 p.m. EDT, approaching its best level of the day. The Dow largely ignored a slight drop in consumer confidence and some signs of weakness in the housing market , as a relatively solid earnings...
Here's What You Don't Know About Merck & Co. Inc., Today's Best Dow Stock
Alex Planes, The Motley Fool - Motley Fool - Tue Apr 29, 11:13AM CDT
The Dow Jones Industrial Average is off to a solid start in April's final week, and its pharmaceutical components have been major contributors. Pfizer paced Monday's index gain as it pursued another megabuyout , and today's pop is led by ...
Could This Be the Next Health Care Acquisition Target?
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 29, 11:05AM CDT
If you follow the health-care sector in any way, shape, or form, the pay week and a half has been nothing short of incredible. Merger and acquisition activity usually comes in spurts, and true megadeals are rare . But in recent days we have been...
Bristol-Myers Beats Earnings in Q1, Misses on Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 10:52AM CDT
Bristol-Myers (BMY) first quarter 2014 adjusted earnings of 46 cents per share beat the Zacks Consensus Estimate by 2 cents.
Early Glance: Pharmaceuticals companies
AP - Tue Apr 29, 9:30AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Stock Market News for April 29, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 9:06AM CDT
Benchmarks finished Monday’s choppy run mostly higher as investor sentiment following new deals in the health care sector, positive pending home sales data and intense selling pressure on internet stocks
The 3 Reasons Pfizer Wants AstraZeneca
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Apr 29, 8:30AM CDT
Pfizer admitted this morning that it has approached AstraZeneca twice seeking an opportunity to buy the company, most recently last weekend. In a conference call with analysts on Monday, Pfizer's management laid out the case for why AstraZeneca...
Report: Health exchanges' drug coverage confusing
By CARLA K. JOHNSON - AP - Tue Apr 29, 6:03AM CDT
CHICAGO (AP) — The hunt for a health plan that would cover a particular drug or a favorite doctor proved particularly frustrating for many consumers navigating the new insurance exchanges under the federal government's health care overhaul, according to a report released Monday.
'Fast Money' Recap: The Problem With Growth Stocks
at The Street - Tue Apr 29, 4:00AM CDT
The trading panel wonders why Facebook is having a good quarter when Google has been selling off.
